United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 70,389 shares of the biotechnology company’s stock after purchasing an additional 4,110 shares during the period. CANADA LIFE ASSURANCE Co owned approximately 0.16% of United Therapeutics worth $24,800,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics during the fourth quarter worth about $25,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics during the 4th quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB raised its position in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Anchor Investment Management LLC raised its holdings in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 30 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $955,319.67. This represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $283.78, for a total value of $3,121,580.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $10,437,712.18. This trade represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 91,500 shares of company stock valued at $30,971,540 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have issued reports on UTHR shares. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Stock Down 0.2 %

Shares of NASDAQ UTHR opened at $284.73 on Friday. The firm’s 50-day simple moving average is $316.61 and its 200 day simple moving average is $348.63. The stock has a market cap of $12.79 billion, a P/E ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $233.28 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.